Work

POSTER: MPN-336 Selinexor Plus Ruxolitinib in JAK Inhibitor (JAKi) Treatment-Naïve Patients With Myelofibrosis: Updated Results and Subgroup Analyses from XPORT-MF-034

Year: 2023

Type: article

Source: Clinical Lymphoma Myeloma & Leukemia

DOI: 10.1016/s2152-2650(23)00665-1

Authors: Haris Ali, Ashwin Kishtagari, Keri Maher, Sanjay Mohan, Josef Prchal, Xulong Wang, Kamal Chamoun, Srinivas Tantravahi

Institutions: City Of Hope National Medical Center, City of Hope, Istituto di Ematologia di Bologna, University Hospital in Halle, Vanderbilt University, Vanderbilt-Ingram Cancer Center, VCU Massey Comprehensive Cancer Center, University of Utah, Huntsman Cancer Institute, Bristol-Myers Squibb (United States), Karyopharm Therapeutics (United States)

Language: English

Topic: Myeloproliferative Neoplasms: Diagnosis and Treatment

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4386271024

FWCI:

Cites:

Cited by:

Related to: 10